Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years, with chronic genotype 1 HCV infection~* HCV RNA equal to or greater than 10,000 IU/mL at screening~* Cirrhosis determination; a liver biopsy may be required~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Current or prior history of clinical hepatic decompensation~* Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 8 Weeks (TN) (Type: EXPERIMENTAL): Treatment-naive (TN) participants will be randomized to receive LDV/SOF for 8 weeks.
- LDV/SOF+RBV 8 Weeks (TN) (Type: EXPERIMENTAL): Treatment-naive participants will be randomized to receive LDV/SOF plus RBV for 8 weeks.
- LDV/SOF 12 Weeks (TN) (Type: EXPERIMENTAL): Treatment-naive participants will be randomized to receive LDV/SOF for 12 weeks.
- LDV/SOF 12 Weeks (TE) (Type: EXPERIMENTAL): Treatment-experienced (TE) participants (had virologic failure following prior therapy with a protease-inhibitor \[PI\]+pegylated interferon \[PEG\]+RBV regimen) will be randomized to receive LDV/SOF for 12 weeks.
- LDV/SOF+RBV 12 Weeks (TE) (Type: EXPERIMENTAL): Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) will be randomized to receive LDV/SOF plus RBV for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).